Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer: A Single-armed, Phase II Trial

NCT05300958 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05300958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05300958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer: A Single-armed, Phase II Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Terminated
Start date
March 21, 2022
Completion date
July 21, 2025
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer